Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Non-Current Assets (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Other Non-Current Assets data on record, last reported at $852000.0 in Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 238.1% year-over-year to $852000.0; the TTM value through Sep 2025 reached $852000.0, up 238.1%, while the annual FY2024 figure was $632000.0, 610.11% up from the prior year.
  • Other Non-Current Assets reached $852000.0 in Q3 2025 per CRVS's latest filing, up from $626000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $852000.0 in Q3 2025 and bottomed at $89000.0 in Q3 2023.
  • Average Other Non-Current Assets over 4 years is $299600.0, with a median of $236000.0 recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: plummeted 64.11% in 2023, then soared 610.11% in 2024.
  • A 4-year view of Other Non-Current Assets shows it stood at $129000.0 in 2022, then plummeted by 31.01% to $89000.0 in 2023, then skyrocketed by 610.11% to $632000.0 in 2024, then soared by 34.81% to $852000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $852000.0 in Q3 2025, $626000.0 in Q2 2025, and $629000.0 in Q1 2025.